Author

Ryan Abbott

  • Intellectual Property

    Beyond the Patents-Prizes Debate

    By Ryan Abbott In Beyond the Patents-Prizes Debate (forthcoming in the Texas Law Review), Daniel Hemel and Lisa Larrimore Ouellette articulate a new theoretical framework for thinking about R&D funding mechanisms. They note that patents,…

    Beyond the Patents-Prizes Debate

  • Global Health

    Of Evergreening and Efficacy, Part III

    By Ryan Abbott This is the last in a three-part series (Part I, Part II) of posts I’ve written about the case between Novartis and the Union of India, in which the Supreme Court of India…

    Of Evergreening and Efficacy, Part III

  • Global Health

    Of Evergreening and Efficacy, Part II

    By Ryan Abbott I wrote earlier this month about the case between Novartis and the Union of India, in which the Supreme Court of India affirmed denying a patent for Novartis’ anti-cancer drug Glivec. Adriana Benedict added an…

    Of Evergreening and Efficacy, Part II

  • Biotechnology

    Of Evergreening and Efficacy

    By Ryan Abbott An important case was decided yesterday that may have a significant impact on access to medicines for patients in developing countries. India’s high court rejected an appeal by the pharmaceutical company Novartis…

    Of Evergreening and Efficacy